4-Fluoromethylphenidate

4-Fluoromethylphenidate
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C14H18FNO2
Molar mass 251.3 g/mol
3D model (JSmol)

4-Fluoromethylphenidate (also known as 4-FMPH and 4F-MPH) is a stimulant drug that acts as a higher efficiency dopamine reuptake inhibitor than the closely related methylphenidate.[1][2][3]

4-Fluoromethylphenidate was studied further along with other analogues of (±)-threo-methylphenidate (TMP) to assess their potential as anti-cocaine medications. 4F-MPH was reported as having an ED50 mg/kg of 0.26 (0.18–0.36) and a relative potency of 3.33 to Methylphenidate.[4]

Another study found that in the threo-isomers of methylphenidate, the meta- and para-substituted compounds with electron-withdrawing substituents tended to have increased binding potency. Compounds containing fluorine, chlorine, bromine and methyl groups were reported to be more potent than methylphenidate. 4F-MPH was reported as having the following values: [3H]WIN 35428 binding of 35.0 ± 3.0 (2) and [3H]dopamine 142 ± 2.0 (2).[5]

4-Fluoromethylphenidate is a Schedule I controlled substance in the US state Alabama.[6] As of 5 May 2017, 4-fluoromethylphenidate is a controlled substance in Canada.[7]

See also

References

  1. ↑ Huw M.L. Davies; Darrin W. Hopper; Tore Hansen; Quixu Liu; Steven R. Childers (April 2004). "Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites". Bioorganic & Medicinal Chemistry Letters. 14 (7): 1799–1802. PMID 15026075. doi:10.1016/j.bmcl.2003.12.097.
  2. ↑ Milind Misra; Qing Shi; Xiaocong Ye; Ewa Gruszecka-Kowalik; Wei Bu; Zhanzhu Liu; Margaret M. Schweri; Howard M. Deutsch; Carol A. Venanzi (October 2010). "Quantitative structure–activity relationship studies of threo-methylphenidate analogs". Bioorganic & Medicinal Chemistry. 18 (20): 7221–7238. PMID 20846865. doi:10.1016/j.bmc.2010.08.034.
  3. ↑ Satendra Singh (February 2000). "Chemistry, Design, and Structure−Activity Relationship of Cocaine Antagonists". Chemical Reviews. 100 (3): 925–1024. PMID 11749256. doi:10.1021/cr9700538.
  4. ↑ M. M. Schweri; H. M. Deutsch; A.T. Massey; S. G. Holtzman (May 2002). "Biochemical and Behavioral Characterization of Novel Methylphenidate Analogs". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 527–535. PMID 11961053. doi:10.1124/jpet.301.2.527.
  5. ↑ Howard M. Deutsch; Qing Shi; Ewa Gruszecka-Kowalik; Margaret M. Schweri (March 1996). "Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structure−Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate Analogs". Journal of Medicinal Chemistry. 39 (6): 1201–1209. PMID 8632426. doi:10.1021/jm950697c.
  6. ↑ "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd.". March 2014. Retrieved 28 September 2015.
  7. ↑ Regulations Amending the Food and Drug Regulations (Part G — Methylphenidate)-4-Fluoromethylphenidate (methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate). http://www.gazette.gc.ca/rp-pr/p2/2017/2017-04-05/html/sor-dors43-eng.php
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.